Revolution Medicines, Inc. (NASDAQ: RVMD) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -3.04 | Insider Own | 3.69% | Shs Outstand | 212.60M | Perf Week | -2.99% |
| Market Cap | 38.79B | Forward P/E | - | EPS next Y | -5.30 | Insider Trans | -4.85% | Shs Float | 190.10M | Perf Month | -3.59% |
| Enterprise Value | 37.30B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 7.37% | Perf Quarter | 30.81% |
| Income | -296.00M | P/S | - | EPS this Y | -160.16% | Inst Trans | - | Short Ratio | 4.33 | Perf Half Y | 88.19% |
| Sales | 29.00M | P/B | 25.86 | EPS next Y | 33.00% | ROA | -60.86% | Short Interest | 14.00M | Perf YTD | 129.06% |
| Book/sh | 7.06 | P/C | 20.33 | EPS next 5Y | - | ROE | -83.22% | 52W High | 206.29 -6.22% | Perf Year | 389.54% |
| Cash/sh | 8.97 | P/FCF | - | EPS past 3/5Y | - | ROIC | -70.02% | 52W Low | 36.05 436.62% | Perf 3Y | 624.87% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 3.97% 3.73% | Perf 5Y | 552.07% |
| Dividend TTM | - | EV/Sales | - | EPS Y/Y TTM | 15.08% | Oper. Margin | 0.00% | ATR (14) | 7.38 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.80 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 50.84 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.80 | EPS Q/Q | -102.65% | SMA20 | -1.82% | Beta | 1.38 | Target Price | 194.09 |
| Payout | 0.00% | Debt/Eq | 0.09 | Sales Q/Q | - | SMA50 | 5.92% | Rel Volume | 0.68 | Prev Close | 182.45 |
| Employees | 883 | LT Debt/Eq | 0.09 | Earnings | Aug 05 | SMA200 | 57.12% | Avg Volume | 2.69M | Price | 193.46 |
| IPO Date | Feb 13, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -24.75% - | Net Debt/EBITDA | 0.00 | Volume | 1,824,229 | Change | 6.03% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-23-26 | Reiterated | Wedbush | Outperform | $181 → $192 |
| Jul-09-26 | Reiterated | Guggenheim | Buy | $205 → $235 |
| Jul-06-26 | Reiterated | Mizuho | Outperform | $143 → $215 |
| Jul-02-26 | Reiterated | Wedbush | Outperform | $147 → $181 |
| Jun-30-26 | Reiterated | Truist Securities | Buy | $179 → $210 |
| Jun-29-26 | Reiterated | Needham | Buy | $61 → $235 |
| Jun-09-26 | Reiterated | UBS | Buy | $170 → $175 |
| Jun-02-26 | Reiterated | RBC Capital | Outperform | $162 → $182 |
| Jun-01-26 | Reiterated | Oppenheimer | Outperform | $165 → $195 |
| Jun-01-26 | Reiterated | HC Wainwright & Co. | Buy | $169 → $195 |
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 29 | 0 | 0 | 12 | 35 | 29 | 43 | 50 | 20 | |
| Cost of Goods Sold Incl. D&A | 0 | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Gross Profit | 29 | -17 | 0 | 12 | 35 | 29 | 43 | 50 | 20 | |
| Selling, General and Administrative Excl. Other | 49 | 187 | 97 | 76 | 41 | 30 | 21 | 12 | 9 | |
| Research and Development | 302 | 979 | 592 | 423 | 253 | 187 | 132 | 92 | 51 | |
| Other Operating Expense | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | |
| Operating Income | -323 | -1,182 | -690 | -487 | -258 | -188 | -111 | -54 | -40 | |
| Interest Expense | 0 | 24 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 25 | 75 | 89 | 48 | 9 | 1 | 2 | 2 | -1 | |
| Net Income Before Taxes | -297 | -1,131 | -601 | -440 | -249 | -187 | -109 | -52 | -42 | |
| Income Taxes | 0 | 0 | -1 | -4 | 0 | 0 | 0 | -4 | 0 | |
| Consolidated Net Income | -296 | -1,131 | -600 | -436 | -249 | -187 | -108 | -48 | -42 | |
| Net Income From Continuing Operations | -296 | -1,131 | -600 | -436 | -249 | -187 | -108 | -48 | -42 | |
| Net Income | -296 | -1,131 | -600 | -436 | -249 | -187 | -108 | -48 | -42 | |
| EPS (Recurring) | -3.04 | -5.95 | -3.58 | -3.86 | -3.08 | -2.47 | -1.62 | -1.31 | -1.15 | |
| EPS (Basic, Before Extraordinaries) | -3.04 | -5.95 | -3.58 | -3.86 | -3.08 | -2.47 | -1.62 | -1.31 | -1.15 | |
| EPS (Diluted) | -3.04 | -5.95 | -3.58 | -3.86 | -3.08 | -2.47 | -1.62 | -1.31 | -1.15 | |
| EBITDA | -288 | -1,091 | -589 | -430 | -239 | -180 | -102 | -49 | -40 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 713.80 | — | — | 270.07 | 55.13 | 63.36 | 61.69 | — | — | |
| Gross Margin | 100.00 | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
| Operating Margin | -1,113.79 | — | — | -4,058.33 | -737.14 | -648.28 | -258.14 | -108.00 | -200.00 | |
| Net Margin | -1,020.69 | — | — | -3,633.33 | -711.43 | -644.83 | -251.16 | -96.00 | -210.00 | |
| Shares Outstanding | 107 | 190 | 168 | 113 | 81 | 73 | 67 | 36 | 36 | |
| Market Capitalization | 20,700 | 15,134 | 7,348 | 3,241 | 1,929 | 1,837 | 2,653 | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Patel Sushil | Director | Jun 29 '26 | Sale | 187.99 | 5,580 | 1,048,968 | 21,656 | Jul 01 |
| Patel Sushil | Director | Jun 29 '26 | Option Exercise | 37.54 | 2,955 | 110,931 | 27,236 | Jul 01 |
| Anders Jack | Chief Financial Officer | Jun 24 '26 | Option Exercise | 18.56 | 40,000 | 742,400 | 143,269 | Jun 26 |
| Anders Jack | Chief Financial Officer | Jun 24 '26 | Sale | 168.33 | 20,000 | 3,366,604 | 123,269 | Jun 26 |
| Mancini Anthony | See Remarks | Jun 16 '26 | Sale | 156.12 | 4,615 | 720,490 | 49,975 | Jun 18 |
| Cislini Jeff | General Counsel | Jun 16 '26 | Sale | 156.12 | 2,157 | 336,749 | 56,521 | Jun 18 |
| GOLDSMITH MARK A | See Remarks | Jun 16 '26 | Sale | 156.12 | 10,020 | 1,564,310 | 267,330 | Jun 18 |
| Anders Jack | Chief Financial Officer | Jun 16 '26 | Sale | 156.12 | 2,722 | 424,956 | 123,269 | Jun 18 |
| Kelsey Stephen Michael | See Remarks | Jun 16 '26 | Sale | 156.12 | 4,175 | 651,798 | 291,876 | Jun 18 |
| Horn Margaret A | Chief Operating Officer | Jun 17 '26 | Sale | 160.12 | 29,600 | 4,739,679 | 154,647 | Jun 17 |
| Horn Margaret A | Chief Operating Officer | Jun 17 '26 | Option Exercise | 27.14 | 29,600 | 803,457 | 184,247 | Jun 17 |
| Horn Margaret A | Chief Operating Officer | Jun 15 '26 | Sale | 160.17 | 60,400 | 9,674,304 | 158,222 | Jun 17 |
| Horn Margaret A | Chief Operating Officer | Jun 15 '26 | Option Exercise | 32.62 | 60,400 | 1,969,993 | 218,622 | Jun 17 |
| Horn Margaret A | Chief Operating Officer | Jun 16 '25 | Sale | 98.51 | 7,085 | 697,929 | 150,675 | Jun 17 |
| Horn Margaret A | Chief Operating Officer | Jun 11 '26 | Sale | 148.01 | 10,000 | 1,480,139 | 158,222 | Jun 15 |